Professor Tien-Lu Cheng, Director of Research & Development at Kaohsiung Medical University and a veteran antibody researcher of 30 years, leads a team that developed three breakthrough technologies—anti-PEG antibodies, the Antibody Lock, and bispecific targeted therapies. To date, these innovations have generated over NT$100 million in tech-transfer revenue.
The KMU team has actively participated in international biotech exhibitions and global tech-transfer activities, expanding their international visibility. Their “Antibody Lock” technology enables antibodies to remain inactive until trigger-activated in disease sites, thereby enhancing therapeutic selectivity and reducing systemic side effects. This technology has been adapted for more than 10 existing marketed antibodies, and partnerships with global pharma companies are underway, with commercial potential estimated at over USD 1 billion.
